SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Moleculin Biotech Completes MIRACLE Trial Part A Dosing

Moleculin Biotech completed dosing in Part A of its pivotal MIRACLE trial of AnnAraC for relapsed or refractory AML. Comprehensive data are expected in Q1 2027.

MBRX

Related stories